Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. The trade was a 7.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Arrowhead Pharmaceuticals Trading Down 8.6 %

Shares of Arrowhead Pharmaceuticals stock opened at $20.36 on Thursday. The firm has a market capitalization of $2.53 billion, a PE ratio of -4.06 and a beta of 0.91. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The firm’s 50 day moving average is $21.20 and its 200 day moving average is $23.12. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Fifth Third Bancorp increased its holdings in Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 354 shares in the last quarter. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Meeder Asset Management Inc. increased its position in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the period. nVerses Capital LLC bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $96,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARWR has been the topic of several research reports. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein lowered their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $42.70.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.